Sociodemographic and pharmacological characteristics of patients with primary and secondary Raynaud's phenomenon. A cross-sectional study
Open Access
- 29 May 2025
- journal article
- Published by Elsevier in Vascular Diseases
- Vol. 50 (3-4) , 99-103
Abstract
No abstract availableKeywords
Funding Information
- Universidad Tecnológica de Pereira
This publication has 18 references indexed in Scilit:
- Clinically relevant differences between primary Raynaud's phenomenon and secondary to connective tissue diseaseSeminars in Arthritis and Rheumatism, 2024
- Biases arising from linked administrative data for epidemiological research: a conceptual framework from registration to analysesEuropean Journal of Epidemiology, 2022
- Part I: Epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenonJournal of the American Academy of Dermatology, 2022
- Part II: The treatment of primary and secondary Raynaud's phenomenonJournal of the American Academy of Dermatology, 2022
- How do patients define Raynaud’s phenomenon? Differences between primary and secondary diseaseClinical Rheumatology, 2021
- Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic reviewPharmacology Research & Perspectives, 2020
- Raynaud's phenomenonBest Practice & Research Clinical Rheumatology, 2020
- Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trialsThe Lancet Rheumatology, 2019
- Raynaud’s phenomenon—an update on diagnosis, classification and managementClinical Rheumatology, 2019
- Raynaud’s phenomenon in Northern Sweden: a population-based nested case–control studyRheumatology International, 2018